Abstract:This issue of Appl Immunohistochem Mol Morphol contains an important study highlighting the efforts of the Canadian immunohistochemistry Quality Control Group (cIQc), a novel and timely approach for the quality assurance (QA) of breast marker immunohistochemistry (IHC). Are there lessons that can be learned from this Canadian study, and are there implications for breast marker IHC testing in the United States? Let me first make a few disclaimers: I am one of the authors of, and participants in, the cIQc program study, and I also serve as a member of the IHC Committee of the College of American Pathology (CAP), which has oversight of the proficiency testing (PT) program for human epidermal growth factor receptor-2 (HER2) [(and, soon, estrogen receptor (ER)] testing as mandated by the American Society of Clinical Oncology (ASCO)-CAP guidelines. But the voice of this editorial is my personal one, and does not reflect the views of either the cIQc or the CAP. One must be very clear about the role of QA methodologies in breast marker IHC: do they represent assessments of quality, or do they represent tools to improve quality? Although these may not be mutually exclusive, there are important real and potential implications and consequences of the answer to that question. For one of the compelling motivators for the development and employment of QA systems in breast marker IHC has been the unsatisfactory job that we, as a pathology community, seem to be doing in this regard. Before the implementation of the ASCO-CAP guidelines, it seemed to be that the error rate of HER2 IHC testing in breast cancer in the United States was on the order of 20%, with most of these representing false positives, when comparing with either ‘central laboratory’ IHC or fluorescence in situ hybridization (FISH). Error rates of ER testing in the United States are essentially unknown, as there have been almost no comparable published studies documenting interlaboratory error rates as there are with HER2. And those few studies do suggest there is also a big problem with ER testing. Although American pathologists may be aghast at the high error rates in ER testing that were apparent in the recent debacle in Newfoundland, which has resulted in many ER positive breast cancer patients being misclassified as ER negative and thus denied hormonal targeted therapy, I am not sure how much better many United States laboratories would fare in a similar retesting scheme. The use of QA programs to give a report card on general laboratory performance can be problematic at best and disingenuous at worst. The very high concordance data evident in this cIQc study is not necessarily reassuring, as these authors would be the first to point out that the participants in this QA study represent ‘‘expert’’ laboratories. Even the CAP’s PT program represents a selfselected group and may not reflect the true state of testing in the entire community. Indeed, studies that retrospectively retest actual patient specimens either in a central lab, using either IHC or another methodology such as FISH, represent a more accurate, ‘real world’ assessment of the state of HER2 IHC testing, and seem to provide a much darker view of the quality of these studies as performed in the United States. How does the Canadian approach, as exemplified in this cIQc program, differ from that of the United States? On a practical level, participation in this Canadian program is anonymous; participation in CAP sponsored PT in the United States is

A neural network based DSS for advising students in the school of business

[The effect of monoamine oxidase inhibitors and reserpine on the gamma-aminobutyric acid content of the rat brain].

[Cushing syndrome: Physiopathology, etiology and principles of therapy]

Tweaking and nudging toward improved-IHC quality.

Medical therapy of endogenous Cushing’s syndrome with steroidogenesis inhibitors: treatment rationale, available drugs, and therapeutic effects.

Medical Management of Cushing’s Syndrome: Current and Emerging Treatments

Toward a Diagnostic Score in Cushing's Syndrome

Drug development and potential targets for Cushing's syndrome

Cushing syndrome from an ACTH-producing pheochromocytoma or paraganglioma: structured review of 94 cases

Pilot study of early corticosteroid elimination after pancreas transplantation.

Psychiatric Symptoms in Patients with Cushing’s Syndrome: Prevalence, Diagnosis and Management

Simulated Density Currents beneath Embedded Stratified Layers

Expression of reactive oxygen species-related proteins in metastatic breast cancer is dependent on the metastatic site.

A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes.

Cognitive decline in Cushing's syndrome: A systematic review

Diagnostic and management challenges in paediatric Cushing's syndrome

Timing of caffeine therapy in very low birth weight infants.

Difficult Diagnosis and Management of Concealed Cushing

Cushing's Syndrome: A Large Adenoma of Adrenal Gland

Cushing's syndrome in women with polycystic ovaries and hyperandrogenism

Medical Treatment of Cushing's Disease: An Overview of the Current and Recent Clinical Trials